Benzo[a]pyrene (3,4-Benzopyrene)
(Synonyms: 苯并[a]芘; 3,4-Benzopyrene) 目录号 : GC32985Benzo[a]pyrene (3,4-Benzopyrene) (BaP, B[a]P)是一种由苯环与芘熔合而成的多环芳烃。
Cas No.:50-32-8
Sample solution is provided at 25 µL, 10mM.
Benzo[a]pyrene (3,4-Benzopyrene) (BaP, B[a]P) is a polycyclic aromatic hydrocarbon formed by a benzene ring fused to pyrene[1]. The diol epoxide metabolites of Benzo[a]pyrene (3,4-Benzopyrene), BPDE, react with and bind to DNA, resulting in mutations and carcinogenesis[2]. Benzo[a]pyrene (3,4-Benzopyrene) has toxicity on the nervous system, immune system, reproductive system, and carcinogenicity[3].
In vitro Benzo[a]pyrene (3,4-Benzopyrene) (0.2µg/ml; 24h) induces the transformation of human mammary epithelial cells[4]. Benzo[a]pyrene (3,4-Benzopyrene) (1,5, 10μM; up to 6 days) also confers enhanced susceptibility to bacterial infection[5]. The carcinogenesis caused by Benzo[a]pyrene (3,4-Benzopyrene) (0.05-500μg/ml; 24h) can be restored by isoflavone biochanin A[6].
In vivo Benzo[a]pyrene (3,4-Benzopyrene) (300μg/kg; 3 days; oral gavage) results in diminished mRNA expression of the NMDA NR2B receptor subunit to resulting in late-life deficits in cortical neuronal activity in the offspring[7]. Benzo[a]pyrene (3,4-Benzopyrene) (150µg/kg; once per day for 30 days; oral gavage) also increases 7-ethoxyresorufin-O-deethylase activity in liver microsomal fraction[8].
References:
[1] Bukowska, Bożena et al. “Benzo[*a*]pyrene-Environmental Occurrence, Human Exposure, and Mechanisms of Toxicity.” *International journal of molecular sciences* vol. 23,11 6348. 6 Jun. 2022, doi:10.3390/ijms23116348
[2] Matter, Brock et al. “Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences.” *Chemical research in toxicology* vol. 17,6 (2004): 731-41. doi:10.1021/tx049974l
[3] Fu, Chenghao et al. “Benzo(a)pyrene and cardiovascular diseases: An overview of pre-clinical studies focused on the underlying molecular mechanism.” *Frontiers in nutrition* vol. 9 978475. 4 Aug. 2022, doi:10.3389/fnut.2022.978475
[4] Stampfer, M R, and J C Bartley. “Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene.” *Proceedings of the National Academy of Sciences of the United States of America*vol. 82,8 (1985): 2394-8. doi:10.1073/pnas.82.8.2394
[5] Clark, Ryan S et al. “Validation of research trajectory 1 of an Exposome framework: Exposure to benzo(a)pyrene confers enhanced susceptibility to bacterial infection.” *Environmental research* vol. 146 (2016): 173-84. doi:10.1016/j.envres.2015.12.027
[6] Cassady, J M et al. “Use of a mammalian cell culture benzo(a)pyrene metabolism assay for the detection of potential anticarcinogens from natural products: inhibition of metabolism by biochanin A, an isoflavone from Trifolium pratense L.” *Cancer research* vol. 48,22 (1988): 6257-61.
[7] McCallister, Monique M et al. “Prenatal exposure to benzo(a)pyrene impairs later-life cortical neuronal function.” *Neurotoxicology* vol. 29,5 (2008): 846-54. doi:10.1016/j.neuro.2008.07.008
[8]Kang, Hwan Goo et al. “Changes of biomarkers with oral exposure to benzo(a)pyrene, phenanthrene and pyrene in rats.” *Journal of veterinary science*vol. 8,4 (2007): 361-8. doi:10.4142/jvs.2007.8.4.361
Benzo[a]pyrene (3,4-Benzopyrene) (BaP, B[a]P)是一种由苯环与芘熔合而成的多环芳烃[1]。Benzo[a]pyrene (3,4-Benzopyrene)的二醇环氧化物代谢产物BPDE与DNA反应并结合,导致突变和致癌[2]。Benzo[a]pyrene (3,4-Benzopyrene)对神经系统、免疫系统、生殖系统具有毒性[3]。
在体外,Benzo[a]pyrene (3,4-Benzopyrene) (0.2µg/ml; 24h) 诱导人乳腺上皮细胞的体外癌变转化[4]。Benzo[a]pyrene (3,4-Benzopyrene) (1,5, 10μM; up to 6 days)也会增加细胞对细菌感染的易感性[5]。Benzo[a]pyrene (3,4-Benzopyrene) (0.05 ~ 500μg/ml)的致癌性能够被异黄酮生物茶素A扭转[6]。
在体内,Benzo[a]pyrene (3,4-Benzopyrene) (300μg/kg; 3天;口服灌胃)导致NMDA NR2B受体亚基mRNA表达减少,从而导致后代脑皮层神经元活动的晚年缺陷[7]。Benzo[a]pyrene (3,4-Benzopyrene) (150µg/kg; 30天; 口服灌胃) 也增加肝微粒体部分中7-乙氧基间苯甲醚-o-去乙基酶的活性[8]。
Cell experiment [1]: | |
Cell lines | human CD14+ monocytes |
Preparation Method | Cells were cultured in complete RPMI 1640 supplemented with or without benzo(a)pyrene, Benzo[a]pyrene (3,4-Benzopyrene) (1, 5 or 10μM) and M-CSF (50U/mL) for 6 days. After 6 days the cells were washed, incubated with 1mg/mL FITC-dextran for 1h at 37°C. Cellular uptake of FITC-dextran was monitored by flow cytometry. |
Reaction Conditions | 1,5, 10μM; up to 6 days |
Applications | Exposure of macrophages to Benzo[a]pyrene (3,4-Benzopyrene) alters their lipid raft integrity by decreasing membrane cholesterol 25% while increasing CD32 into non-lipid raft fractions. |
Animal experiment [2]: | |
Animal models | Eight-week-old female Slc : SD rats |
Preparation Method | One group of rats was treated with Benzo[a]pyrene (3,4-Benzopyrene)(BaP) alone and another with Benzo[a]pyrene (3,4-Benzopyrene) with phenanthrene (PH) and pyrene (PY) simultaneously given by oral gavage once per day for 30 days at a volume of 2ml/kg and maintained for another three weeks after withdrawal. Muscle, fat, blood, liver and urine samples were collected every 10 days during treatment and every 7 days after withdrawal of the treatment. |
Dosage form | 150µg/kg; once per day for 30 days; oral gavage |
Applications | 7-ethoxyresorufin-O-deethylase activity in liver microsomal fraction was increased in only Benzo[a]pyrene (3,4-Benzopyrene) groups |
References: |
Cas No. | 50-32-8 | SDF | |
别名 | 苯并[a]芘; 3,4-Benzopyrene | ||
Canonical SMILES | C12=C(C=C3)C=C(C=CC=C4)C4=C1C=CC5=CC=CC3=C25 | ||
分子式 | C20H12 | 分子量 | 252.31 |
溶解度 | DMSO : 50 mg/mL (198.17 mM) | 储存条件 | Store at 2-8°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.9634 mL | 19.8169 mL | 39.6338 mL |
5 mM | 0.7927 mL | 3.9634 mL | 7.9268 mL |
10 mM | 0.3963 mL | 1.9817 mL | 3.9634 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet